VAIA
ALNY icon

Virtus Alternative Investment Advisers’s Alnylam Pharmaceuticals ALNY Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-42
Closed -$5K – 10
2020
Q4 		$5K Sell
42
-41
-49% -$5.47K 0.07% 247
2020
Q3 		$12K Sell
83
-24
-22% -$3.41K 0.22% 46
2020
Q2 		$16K Sell
107
-101
-49% -$13.6K 0.25% 100
2020
Q1 		$23K Buy
+208
New +$24K 0.32% 26

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtus Alternative Investment Advisers's ALNY Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2021, closing a stake of 42 shares — an estimated $5K sold.

Virtus Alternative Investment Advisers first reported a position in ALNY in Q1 2020 and held it in 4 quarters. The position peaked at $23K in Q1 2020. 390 funds tracked by Wall St. Rank hold ALNY as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Alnylam Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 42 Alnylam Pharmaceuticals shares in Q1 2021, an estimated $5K.
  • Virtus Alternative Investment Advisers first reported a position in Alnylam Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Virtus Alternative Investment Advisers's Alnylam Pharmaceuticals position peaked at $23K in Q1 2020.
  • 390 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.